Physician profile
Mary Baker
NPI 1659336972
$9,105.15
in general payments reported to CMS, 2019-2025
57 companies · $2,167 in 2025
The $2,167 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $824 · 2022: $1,619 · 2023: $1,927 · 2024: $2,568 · 2025: $2,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,662.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,289.12 | 2021-2025 | Enhertu, Vanflyta, Injectafer |
| Merck Sharp & Dohme LLC | $803.05 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $736.53 | 2021-2025 | Lynparza, Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $583.94 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $513.68 | 2021-2025 | Opdivo |
| Janssen Biotech, INC. | $459.57 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Eisai INC. | $440.59 | 2021-2025 | |
| Glaxosmithkline, LLC. | $401.07 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Genzyme Corporation | $327.82 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $280.34 | 2021-2025 | Libtayo |
| Lilly USA, LLC | $233.80 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Pharmaessentia USA Corporation | $215.72 | 2023-2025 | Besremi |
| Amgen INC. | $211.63 | 2021-2023 | Xgeva, Nplate, Vectibix |
| Bayer Healthcare Pharmaceuticals INC. | $198.51 | 2021-2024 | |
| Pfizer INC. | $161.53 | 2021-2025 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $159.94 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Qol Medical, LLC | $143.13 | 2024 | Sucraid |
| Sun Pharmaceutical Industries INC. | $135.42 | 2023-2025 | Yonsa, Odomzo |
| Alkermes, INC. | $114.39 | 2025 | Vivitrol |
| Tersera Therapeutics LLC | $111.28 | 2022-2024 | Zoladex |
| Astellas Pharma US INC | $101.48 | 2023-2025 | Xospata, Vyloy |
| Abbvie INC. | $89.44 | 2021-2023 | |
| Caris Mpi, INC. | $89.23 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $80.04 | 2022-2024 | |
| Servier Pharmaceuticals LLC | $71.47 | 2022-2024 | |
| Agios Pharmaceuticals, INC. | $71.47 | 2025 | Pyrukynd |
| Seagen INC. | $63.49 | 2022-2023 | Padcev |
| Emd Serono, INC. | $61.47 | 2023-2025 | Tepmetko |
| Takeda Pharmaceuticals U.S.A., INC. | $60.25 | 2022-2024 | Fruzaqla, Vpriv |
| Genentech USA, INC. | $56.67 | 2021-2024 | Tecentriq, Rozlytrek, Alecensa |
| Rigel Pharmaceuticals, INC. | $52.22 | 2022 | |
| Blueprint Medicines Corporation | $50.47 | 2023-2024 | Ayvakit |
| Stemline Therapeutics INC. | $50.36 | 2024-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $49.32 | 2024 | Ultomiris |
| Novo Nordisk INC | $48.48 | 2025 | Wegovy |
| Array Biopharma INC | $47.85 | 2021-2024 | Braftovi, Mektovi, Tukysa |
| Ipsen Biopharmaceuticals, INC | $47.00 | 2021-2022 | |
| Genmab U.S., INC. | $46.80 | 2022-2024 | Epkinly |
| Exelixis INC. | $39.85 | 2024 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $34.13 | 2023 | Fotivda |
| Deciphera Pharmaceuticals INC. | $33.61 | 2024-2025 | Qinlock, Tgct, Romvimza |
| Pharmacosmos Therapeutics INC. | $31.36 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $29.77 | 2022-2025 | Akynzeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.31 | 2021-2022 | |
| Foundation Medicine, INC. | $28.52 | 2023 | |
| Emmaus Medical, INC. | $22.09 | 2022 | |
| Verastem, INC. | $21.25 | 2025 | Avmapki Fakzynja Co-Pack |
| Myriad Genetic Laboratories, INC. | $20.62 | 2024 | Myrisk |
| Boston Scientific Corporation | $20.46 | 2023 | Watchman Access System |
| Tempus Ai, INC | $20.15 | 2024 | Xt Cdx |
| Jazz Pharmaceuticals INC. | $19.09 | 2021 | |
| Macrogenics, INC. | $18.13 | 2022 | |
| Celgene Corporation | $16.91 | 2025 | Reblozyl |
| Cumberland Pharmaceuticals, INC. | $16.59 | 2024 | Sancuso |
| Morphosys, US INC. | $16.15 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $14.55 | 2022 | |
| Duchesnay USA Incorporated | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.